title: Axillary dissection in breast cancer patients with metastatic sentinel node: to do or not to do? Suggestions from our series.
abstract: Several studies have put to question and evaluated the indication and prognosis of sentinel lymph node biopsy (SNLB) as sole treatment in human breast cancer. We reviewed 1588 patients who underwent axillary surgery. In 239 patients, axillary lymph node dissection (ALND) was performed following positive fine needle aspiration cytology (FNAC), and, in 299 cases, ALND was executed after positive SNLB. The most dramatic result from our data is that patients with either micrometastasis of the sentinel lymph node (SLN) or only metastatic SLN have, respectively, an 84.5% and a 75.0% chance of having no other nodal involvement. We believe a more refined patient selection is neccessary when considering ALND. Where the primary tumor is larger than 5 cm, where radio or adjuvant therapies are not indicated, in cases of FNAC+ nodes, and in cases presenting more than one metastatic sentinel node, we prefer to carry out ALND. Having thus said, however, our data suggests that it is wise not to perform ALND in almost all cases presenting positive SLNs.
authors.affiliation: Ginteam, Mini-Invasive Gynaecological and Breast Unit, Evangelical Hospital, ASL TO1, Corso Marconi 35, 10125 Torino, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Bortolini
authors.forename: F
authors.initials: F
authors.lastname: Genta
authors.forename: Chiara Perono
authors.initials: CP
authors.lastname: Biacchiardi
authors.forename: E
authors.initials: E
authors.lastname: Zanon
authors.forename: M
authors.initials: M
authors.lastname: Camanni
authors.forename: F
authors.initials: F
authors.lastname: Deltetto
references.citation: JAMA. 2011 Feb 9;305(6):569-75
references.pmid: 21304082
references.citation: Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
references.pmid: 12629218
references.citation: J Natl Cancer Inst. 2006 May 3;98(9):599-609
references.pmid: 16670385
references.citation: J Surg Oncol. 1997 Sep;66(1):2-6
references.pmid: 9290685
references.citation: Ann Surg Oncol. 2010 Oct;17 Suppl 3:343-51
references.pmid: 20853057
references.citation: Breast J. 2010 Sep-Oct;16 Suppl 1:S26-8
references.pmid: 21050305
references.citation: J Clin Oncol. 2001 Mar 1;19(5):1539-69
references.pmid: 11230499
references.citation: J Clin Oncol. 2009 Jun 20;27(18):2946-53
references.pmid: 19364968
references.citation: Int J Clin Pract. 2008 Nov;62(11):1785-91
references.pmid: 19143863
references.citation: Ann Surg. 2010 Apr;251(4):595-600
references.pmid: 20195151
references.citation: Semin Surg Oncol. 2001 Apr-May;20(3):230-7
references.pmid: 11523108
references.citation: Ann Oncol. 2005 Mar;16(3):383-8
references.pmid: 15668261
references.citation: J Clin Oncol. 2010 Feb 10;28(5):731-7
references.pmid: 20038733
references.citation: Arch Surg. 2010 Jun;145(6):564-9
references.pmid: 20566977
references.citation: Br J Surg. 2010 May;97(5):680-3
references.pmid: 20186888
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7703-20
references.pmid: 16157938
references.citation: Ann Surg. 2010 Sep;252(3):426-32; discussion 432-3
references.pmid: 20739842
references.citation: N Engl J Med. 2009 Aug 13;361(7):653-63
references.pmid: 19675329
references.citation: Ann Surg. 1994 Sep;220(3):391-8; discussion 398-401
references.pmid: 8092905